Big Money Sentiment increased to 3.06 in 2018 Q2. It has change of 2.17, from 2018Q1’s 0.89. The ratio increased due to STAAR Surgical Company positioning: 8 sold and 23 reduced. 53 funds bought stakes and 42 increased stakes. Investors holded 32.17 million in 2018Q1 but now own 67.83 million shares or 110.85% more.
Arrowstreet Ltd Partnership reported 103,930 shs. Wells Fargo & Mn reported 160,465 shs. Prelude Capital Mgmt Ltd Liability Corp, New York-based fund reported 1,000 shs. Barrow Hanley Mewhinney & Strauss Ltd Liability Company has invested 0% in STAAR Surgical Company (NASDAQ:STAA). 49,717 are held by Parametric Port Limited Liability Com. Great West Life Assurance Can reported 3,523 shs stake. Sg Americas Securities Ltd invested in 10,557 shs. Riverhead Capital Ltd Llc has invested 0.03% in STAAR Surgical Company (NASDAQ:STAA). Clarivest Asset Mngmt Limited Liability Corporation owns 0.07% invested in STAAR Surgical Company (NASDAQ:STAA) for 131,475 shs. Pennsylvania-based Hudock Grp Inc Limited Liability Company has invested 0% in STAAR Surgical Company (NASDAQ:STAA). Products Prns Ltd Liability stated it has 55,689 shs or 0.07% of all its holdings. Northern Trust Corp owns 499,051 shs. Aqr Capital Ltd accumulated 256,131 shs or 0.01% of the stock. Menta Capital Llc invested 0.09% in STAAR Surgical Company (NASDAQ:STAA). Comerica Financial Bank accumulated 36,011 shs.
STAAR Surgical Company registered $206,750 net activity with 0 insider buys and 1 sale since August 20, 2018.
Change of 36.79% for Staar Surgical Company (NASDAQ:STAA)’s shares shorted was showed. FINRA issued shares shorted of STAA’s total 1.17M shares. Previously was reported up change of 36.79% from 857,600 shares. Former STAA’s position will need 3 days to restore. It has 435,800 average volume. Staar Surgical Company’s shares shorted float is 4.23%.
The stock decreased 5.89% or $2.94 during the last trading session, hitting $47.STAAR Surgical Company has 811,682 shares volume, 39.15% up from normal. STAA is uptrending and has moved 312.29% since November 10, 2017. The stock outperformed the S&P500 by 296.67%.
STAAR Surgical Company, together with its subsidiaries, designs, develops, makes, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye.The firm is worth $2.07 billion. The firm provides Visian implantable collamer lenses to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.The P/E ratio is 566.27. It also offers minimally invasive intraocular lenses (IOLs), including foldable IOLs for use in minimally invasive cataract surgical procedures; aspheric IOLs that produce a clearer image than traditional spherical lenses; and nanoFLEX IOL, a single piece collamer aspheric optic, as well as preloaded injectors for use in cataract surgery.
There’s a significant STAAR Surgical Company (NASDAQ:STAA) news posted by Nasdaq.com. It’s a report titled: “Report: Developing Opportunities within Central Garden & Pet, B&G Foods, STAAR Surgical, Forrester Research, QTS …” on November 02, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.